奥希替尼治疗EGFR基因突变型NSCLC患者对其血管新生及外周血Hcy水平的影响

Effects of ocitinib on angiogenesis and peripheral blood Hcy levels in patients with EGFR mutant NSCLC

目的:探讨奥希替尼治疗表皮生长因子受体(EGFR)基因突变型非小细胞肺癌(NSCLC)患者对其血管新生及外周血同型半胱氨酸(Hcy)水平的影响。方法:选取104例EGFR基因突变型NSCLC患者作为研究对象,按照不同的治疗方案分为对照组和观察组,每组各52例。对照组进行培美曲塞+顺铂化疗;观察组在对照组基础上予以奥希替尼治疗。比较两组临床疗效、血管新生指标[血管内皮生长因子(VEGF)、血管生成素2(Ang-2)]水平、外周血Hcy和脑钠肽(BNP)水平和心血管相关不良反应发生情况。结果:观察组疾病控制率(DCR)高于对照组(P<0.05)。治疗后,两组血清VEGF、Ang-2水平均降低(P<0.05),且观察组低于对照组(P<0.05);两组外周血Hcy、BNP水平均升高(P<0.05),且观察组高于对照组(P<0.05)。观察组心血管相关不良反应总发生率高于对照组(P<0.05)。结论:奥希替尼治疗可以抑制EGFR基因突变型NSCLC患者血管新生,提高治疗效果,但也会引起外周血Hcy水平升高,影响心血管功能。

Objective:To explore the effect of oxitinib treatment on angiogenesis and peripheral blood homocysteine(Hcy)levels in patients with epidermal growth factor receptor(EGFR)gene mutant non-small cell lung cancer(NSCLC).Methods:A total of 104 patients with EGFR gene mutant NSCLC were included as study objects,and they were divided into control group and observation group according to different treatment methods,with 52 cases in each group.The control group was treated with pemetrexed+cisplatin chemotherapy,and the observation group was treated with osimertinib on the basis of the control group.The clinical efficacy,angiogenesis indicators[vascular endothelial growth factor(VEGF),angiopoietin-2(Ang-2)]levels,peripheral blood Hcy and brain natriuretic peptide(BNP)levels,cardiovascular-related adverse reactions were compared between the two groups.Results:The disease control rate(DCR)of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of serum VEGF and Ang-2 in the two groups were decreased(P<0.05),and the the observation group were lower than the control group(P<0.05).After treatment,the levels of Hcy and BNP in peripheral blood of the two groups increased(P<0.05),and the observation group were higher than the control group(P<0.05).The total incidence of cardiovascular related adverse reactions in the observation group was higher than that in the control group(P<0.05).Conclusion:Oxetinib adjuvant therapy can inhibit angiogenesis in patients with EGFR gene mutant NSCLC,improve treatment efficacy,but it can also cause increased Hcy levels in peripheral blood and affect cardiovascular function.